Bionano Genomics (BNGO) has entered into a software marketing agreement with Revvity (RVTY) under which Revvity will market and commercialize Bionano’s VIA software as part their newborn sequencing research workflow. VIA is expected to enhance the comprehensive reporting capabilities of Revvity’s sequencing solution by adding an assessment of CNVs to its NGS workflow and streamlining the workflow’s interpretation capabilities. Revvity’s end-to-end workflow includes DNA extraction of dried blood spot samples, sample quality control and quantification, automated library preparation, sequencing, using systems from Element Biosciences or Illumina, a hybridization-based NGS panel designed to identify variants in over 390 genes that are relevant for newborn sequencing research, cloud-based data management, and analysis with VIA software.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
- Bionano: AMA establishes new category I CPT code for OGM in malignacy analysis
- Bionano Genomics files to sell 12.25M share of common stock for holders
- Bionano Genomics announces presence at upcoming cytogenetics conferences
- BioNano Genomics Secures Funding, Redeems Debt, Eyes Future Growth